The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

This study has been completed.
Sponsor:
Collaborator:
Chelsea and Westminster NHS Foundation Trust
Information provided by (Responsible Party):
Kirby Institute
ClinicalTrials.gov Identifier:
NCT01271894
First received: January 5, 2011
Last updated: May 10, 2013
Last verified: November 2012
  Purpose

Safety and efficacy are key issues in antiretroviral therapy (ART) selection. Efavirenz (EFV) is an important component of combination ART in treatment naive individuals. Like many drugs, there are inter-individual differences in the efficacy and tolerability of EFV. The Encore1 study provides an opportunity to examine the pharmacokinetics (PK)(processes by which a drug is absorbed, distributed, metabolized, and eliminated by the body) of EFV in blood samples collected over a 24-hour dosing interval in participants receiving either standard 600 mg or reduced 400 mg dose EFV once daily.


Condition Intervention Phase
HIV Infection
Drug: Efavirenz
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Screening
Official Title: The Intensive Pharmacokinetics Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks

Resource links provided by NLM:


Further study details as provided by Kirby Institute:

Primary Outcome Measures:
  • To compare the pharmacokinetic parameters of EFV determined from blood collected over a 24-hour dosing interval in blinded samples from participants taking either 600 mg or 400 mg once daily in combination with Truvada. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare the safety and tolerability of EFV 400 mg versus 600 mg given once daily. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  • To investigate the correlation between EFV concentration measurements from dried blood spots and concentration measured in matched plasma samples. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: September 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Reduced dose Efavirenz arm
Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
Drug: Efavirenz
400 mg once daily; given as 2 x 200 mg + 1 x placebo
Active Comparator: Normal Efavirenz dose arm
Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
Drug: Efavirenz
600 mg once daily; given as 3 x 200 mg once

Detailed Description:

This sub-study will investigate the relationships between dosage, EFV plasma concentrations, toxicity and virological efficacy. EFV concentrations in dried blood spots and matched plasma and will be evaluated to determine the utility of dried blood spot measurements in measuring EFV plasma concentrations. Measurements dried blood spots could potentially be a cheap and easy alternative to measurements in plasma. Dried blood spots can be easily collected from venous blood or fingerprick, do not need plasma separation and potentially need less stringent storage conditions during shipment.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

All participants enrolled into the main Encore1 study at participating sub-study sites will be eligible to participate.

Participants must meet the following additional inclusion criteria prior to intensive pharmacokinetic assessment. Inclusion Criteria:

  • provide written sub-study consent at or before week 0
  • taken randomized study drugs for at least 4 weeks but less than 8 weeks
  • taken EFV in the evening for at least 7 days
  • taken all EFV doses over the 3 preceding days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01271894

Locations
Argentina
Hospital J.M. Ramos Mejia
Buenos Aires, Argentina
South Africa
Desmond Tutu HIV Foundation
Cape Town, South Africa
Thailand
Thai Red Cross-AIDS Research Centre, HIV-NAT Research Collaboration
Bangkok, Thailand
United Kingdom
Chelsea and Westminister Hospital
London, United Kingdom
Sponsors and Collaborators
Kirby Institute
Chelsea and Westminster NHS Foundation Trust
Investigators
Principal Investigator: Marta Boffito, Dr. Chelsea & Westminster Hospital
  More Information

No publications provided

Responsible Party: Kirby Institute
ClinicalTrials.gov Identifier: NCT01271894     History of Changes
Other Study ID Numbers: NCHECR-ENCORE1-PK
Study First Received: January 5, 2011
Last Updated: May 10, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Kirby Institute:
HIV
efavirenz
pharmacokinetic

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Efavirenz
Reverse Transcriptase Inhibitors
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014